Skip to main content
2/13/2020

Celiac Disease Patients on a Gluten-Free Diet Still Ingest Gluten

Persistent gluten exposure is known to lead to lifelong health issues in people with celiac disease, including anemia, malnutrition, and lymphoma. More and more evidence is showing what many have long suspected: maintaining a truly gluten-free diet may not be possible. Despite the need to protect celiac disease patients against gluten exposure, very little is…

Continue Reading
12/18/2019

Latiglutenase for Celiac Disease Shows Symptom, Quality of Life Improvement

ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe and effective in reducing the symptoms of seropositive celiac disease patients on a gluten-free diet. A significant improvement in both symptom severity and quality of…

Continue Reading
11/20/2019

Role of Gluten Consumption in Childhood Celiac Disease Development

Within the last year, at least three studies were conducted with the goal of determining the relationship between the amount of gluten ingested and the risk of developing celiac disease. An important review of these studies, conducted by Jonas Ludvigsson and CDF Research Committee Member Benjamin Lebwohl, concluded that new clinical trials must be conducted…

Continue Reading
11/20/2019

Gluten-Free Diet & Weight Changes

Researchers at the Beth Israel Deaconess Medical Center, including Celiac Disease Foundation Medical Advisory Board Member Dan Leffler, conducted a study to determine the effects of the gluten-free diet (GFD) on weight changes in celiac patients after diagnosis. The authors note that while weight gain would be welcome and expected in initially underweight patients, similar…

Continue Reading
10/24/2019

Cour Pharmaceuticals Announces Deal with Takeda for Celiac Treatment

Cour Pharmaceuticals has announced a $420 million licensing deal with Takeda Pharmaceuticals following a favorable outcome of their phase 2 trial for celiac disease. The company released data from a small phase 2a study at the annual United European Gastroenterology organization meeting showing that its treatment, CNP-101, cut levels of inflammation-promoting cytokines. The technology was…

Continue Reading
10/3/2019

Preliminary Study Suggests That Risk of Gluten Transfer in Common-Cooking Activities May Be Lower Than Previously Thought

Parents using multiple kitchen appliances and utensils to prevent their child with celiac disease from being exposed to gluten may be able to eliminate some cumbersome steps. A new, preliminary study from Children’s National Hospital published in the journal Gastroenterology found no significant gluten transfer when tools like the same toaster or knives are used for both…

Continue Reading
10/3/2019

Senate Approves NIH Language for Celiac Disease

CEO Marilyn G. Geller’s testimony before the House Appropriations Subcommittee has helped secure report language in the House’s version of the 2020 Labor-HHS-Education bill demanding that the National Institute of Health (NIH) report to Congress in 90 days on its plans to aid celiac disease patients. This acknowledgment that celiac disease is a serious condition…

Continue Reading